Charlie Kimball Secures Partnership with Novo Nordisk, Maker of the Levemir® FlexPen®, for 2010 Firestone Indy Lights Campaign

California native Charlie Kimball has secured sponsorship from Novo Nordisk, a world leader in diabetes care. Kimball will pilot the No. 26 Levemir® FlexPen® car for AFS Racing/Andretti Autosport and will run a full 13-race schedule on the 2010 Firestone Indy Lights series.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Novo Nordisk Inc.

“Charlie Kimball is the perfect example of how people living with diabetes can successfully manage their disease without letting it get in the way of their dreams,” said Camille Lee, Vice President of Diabetes Marketing at Novo Nordisk.

Indianapolis, IN and Princeton, NJ (PRWEB) February 24, 2010

California native Charlie Kimball has secured sponsorship from Novo Nordisk, a world leader in diabetes care. Kimball will pilot the No. 26 Levemir® FlexPen® car for AFS Racing/Andretti Autosport and will run a full 13-race schedule on the 2010 Firestone Indy Lights series.

Kimball, 25, is the only licensed racer with type 1 diabetes in the history of the Indy Racing League. Diagnosed in 2007, he monitors his blood sugar before, during and after each race, and uses Novo Nordisk insulin Levemir® (insulin detemir [rDNA origin] injection) and NovoLog® (insulin aspart [rDNA origin] injection). The partnership with Novo Nordisk includes primary sponsorship of Kimball’s race car, racing suit and helmet. Kimball also will make appearances on behalf of Novo Nordisk throughout 2010.

“Charlie Kimball is the perfect example of how people living with diabetes can successfully manage their disease without letting it get in the way of their dreams,” said Camille Lee, Vice President of Diabetes Marketing at Novo Nordisk. “We are proud of our association with Charlie and we look forward to a successful year on and off the track in 2010.”

Kimball will be competing in his second season in the Firestone Indy Lights series. In 2009, he finished 10th overall, posting a season-best fourth place at Watkins Glen and finishing the 2009 campaign with eight Top 10 results. The 2010 season includes the following race events in 13 cities across North America:

  • March 28: Streets of St. Petersburg (St. Petersburg, Florida)
  • April 11: Barber Motorsports Park (Birmingham, Alabama)
  • April 18: Streets of Long Beach (Long Beach, California)
  • May 28: Indianapolis Motor Speedway (Indianapolis, Indiana)
  • June 19: Iowa Speedway (Newton, Iowa)
  • July 4: Watkins Glen International (Watkins Glen, New York)
  • July 18: Streets of Toronto (Toronto, Ontario, Canada)
  • July 25: Edmonton City Centre Airport (Edmonton, Alberta, Canada)
  • Aug. 8: Mid-Ohio Sports Car Course (Toledo, Ohio)
  • Aug. 22: Infineon Raceway (Sonoma, California)
  • Aug. 28: Chicagoland Speedway (Chicago, Illinois)
  • Sept. 4: Kentucky Speedway (Louisville, Kentucky)
  • Oct. 2: Homestead-Miami Speedway (Miami, Florida)

“This is a big year for me and expectations are high,” Kimball said. “I am fortunate to not only be part of one of the top teams in all of racing at AFS Racing/Andretti Autosport, but to have the support of Novo Nordisk, one of the world’s leading healthcare companies that is committed to helping me live my dream.”

Kimball launched his single-seater racing career in 2002 and has raced in several international series since then, highlighted by a five-win effort in the 2005 British Formula 3 Championship. At that time, Kimball established himself as the first American to win a British Formula 3 race in 11 years.

Prescribing information for Levemir® and NovoLog® is available by contacting Novo Nordisk at 1-800-727-6500 or visiting Levemir-us.com and NovoLog.com.

About Levemir® and NovoLog®
Levemir® (insulin detemir [rDNA origin] injection) is a man-made long-acting insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

NovoLog® (insulin aspart [rDNA origin] injection) is a man-made insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

Important Safety Information for Levemir®
Do not take Levemir® if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in Levemir®. If you take too much Levemir® your blood sugar may fall too low.

Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take Levemir®.

Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.

Never mix Levemir® with other insulin products or use in an insulin pump.

Needles and Levemir® FlexPen® must not be shared.

Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your Levemir® dose may change if you take other medicines.

The most common side effect of Levemir® is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

Important Safety Information for NovoLog®
Do not take NovoLog® if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in NovoLog®. If you take too much NovoLog® your blood sugar may fall too low.

NovoLog® is a fast-acting insulin. You should eat a meal within 5 to 10 minutes after using NovoLog® to avoid low blood sugar. Do not inject NovoLog® if you do not plan to eat right after using NovoLog®. Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take NovoLog®.

Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.

Do not mix NovoLog® with any other insulins when used in a pump or with any insulins other than NPH when used with injections by syringe.

Needles and NovoLog® FlexPen® must not be shared.

Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your NovoLog® dose may change if you take other medicines.

NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

The most common side effect of NovoLog® is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

FlexPen®, Levemir®, and NovoLog® are registered trademarks of Novo Nordisk A/S.

About Charlie Kimball
Kimball, who began racing go-karts at age nine, was accepted into Stanford University and chose to bypass admission to follow his dream to become a racecar driver. Prior to his diabetes diagnosis in 2007, Kimball shattered the European stereotype that “Americans are not fast” by becoming the first American in 11 years to win a British Formula 3 race. He went on to secure two track records and several F3 victories in both Britain and Europe. Kimball has also raced in the Formula 3 Euroseries and the World Series by Renault. This year, Kimball will be competing in the Firestone Indy Lights races throughout the year.

For additional information about Charlie Kimball, visit http://www.charliekimball.com.
Follow Charlie on Twitter at http://twitter.com/racewithinsulin, on his blog, http://www.CharlieKimball.blogspot.com, on YouTube, at http://www.youtube.com/charliekimball, and via the Charlie Kimball Fan Club on Facebook.

About Andretti Autosport
Based in Indianapolis, IN, Andretti Autosport is led by racing legend Michael Andretti. Andretti Autosport, which is the winningest team in Indy Racing League history, fields multiple entries in the IZOD IndyCar Series and also campaigns multiple cars in Firestone Indy Lights in a joint venture with AFS Racing. Andretti Autosport boasts three IZOD IndyCar Series championships (2004, 2005 and 2007), two Firestone Indy Lights titles (2008 and 2009) and has won the Indianapolis 500 twice (2005 and 2007). For more information, please visit http://www.andrettiautosport.com.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.

About Diabetes
In the United States one in 13, or 23.6 million people, have diabetes, a condition in which the body does not produce or properly use insulin, the hormone needed to convert sugar, starches and other food into energy needed for daily life. Poorly or untreated diabetes can lead to a long list of health complications such as heart disease, stroke, kidney disease, high blood pressure, blindness, nerve problems and amputations.

For further information please contact:    

Media:
Al Larsen
Andretti Autosport
317-872-2700

Ambre Morley
Novo Nordisk
609-514-8400

Investors:
Hans Rommer
Novo Nordisk
+45-444-24765

###


Contact

  • Ambre Morley
    Novo Nordisk Inc.
    609-514-8400
    Email
  • Al Larsen
    Andretti Autosport
    317-872-2700
    Email

Attachments